Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy

NCT02205164 is registered in ClinicalTrials.gov with Associazione Salentina Angela Serra as lead sponsor.

NCT NCT02205164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02205164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy
Lead sponsor
Associazione Salentina Angela Serra
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2011
Completion date
October 31, 2014
Enrollment
134 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced nausea and vomiting